New clinical study for children with AML aims to kill leukemia cells and minimize cardiac damage

Cooper is leading a new nationwide clinical trial, conducted within the Children's Oncology Group (COG), for children and adolescents with relapsed acute myelogenous leukemia (AML) to test a drug, CPX-351, which has been designed to kill leukemia cells while minimizing damage to the heart.

Read more: http://www.news-medical.net/news/20161217/New-clinical-study-for-children-with-AML-aims-to-kill-leukemia-cells-and-minimize-cardiac-damage.aspx